Default company panoramic image


CureLauncher solves the clinical trial enrollment problem. It uses a proprietary process to match people to any enrolling clinical trial.

  • Stage Full Product Ready
  • Industry Healthcare Services
  • Location Bloomfield Hills, MI, USA
  • Currency USD
  • Founded August 2012
  • Employees 16
  • Website

Company Summary

CureLauncher uses a proprietary, technology-enabled process that connects large support communities, such as LIVESTRONG and Gilda’s Club, to ANY enrolling clinical trial. There are 10,000 new trials in the U.S. annually. Each trial is delayed by 5 months on average due to enrollment issues. CureLauncher's proprietary ACES (Adaptive Clinical Enrollment System) matches people with chronic diseases to trials based on their unique conditions.


  • Default avatar
    Stephen Goldner
    CEO and Chairman

    Stephen Goldner, Esq. RAC is the FDA regulatory advisor to National Institute of Health. He leads CureLauncher's partnerships with clinical and pharma companies to ensure rapid placement of patients when a clinical trial match is made. He has gotten 230 drugs and medical devices FDA-approved. Mr. Goldner invented the liquid form of methadone, commercialized it and then sold the company to Chesebrough Ponds / Unilever.

  • Default avatar
    David Craig Fuehrer

    David Fuehrer is an innovation expert and has a successful record of new product and service launches globally. David creates CureLauncher's partnerships with support communities to help members enroll in trials. He has managed innovation programs for Pfizer, GE, Dow and others. David has an MBA in Tech Mgmt, from Rochester Institute of Technology and has completed Executive Education at Harvard in Building New Ventures and at MIT in Strategy.


  • Default avatar
    Mark Bennett
    Default avatar
    James Randall

Previous Investors

  • Default avatar
    Stephen Goldner